Table 2

Effect of HAART on CD4+ cell counts and CMV viral load in 22 HIV positive patients, without anti-CMV maintenance therapy, at high risk for developing CMV disease

Patient NoBefore HAARTAfter HAARTLast exam
Exam 0Exam 1Exam 2Exam 3Exam 4Exam 5Exam 6Exam 7After n monthsPCRCD4+
CD4+PCRCD4+PCRPCRPCRCD4+PCRPCRPCRCD4+PCR
11014697011023018130
215091415014018018150
320113621025025012170
42056290220ND9460
540152916013017114018170
6403823020711474NDNDNDNDND10012100
740235510037615058417016# 180
890125917038420019022200
9* 30142390947100NDNDNDND13100
10* 2060414013320020016200
113010237NDNDNDND12180
1220606488146413053460214013120
13203018687540346201672760
141011026017016* 340
152060908017250
1650190NDND130NDNDNDND9130
17307015017016110
18102306017018250
191080ND10013013190
2030140NDNDNDNDNDND8140
21305080ND14130
22* 3012019014840022500
  • CD4+ = CD4+ cell count (cells ×106/l); HAART = highly active antiretroviral therapy; PCR = quantitative polymerase chain reaction, in copies CMV ×106/ml; − = negative result; ND = not done; exam 0 = first examination, at intake, before the start of HAART; exam 1–7 = examinations, monthly, after the start of HAART. After the 7th examination, follow up scheduled every other month, results not shown. *Patient 9, 10, and 22 previous diagnosis of extraocular CMV disease.;patient 7 one positive test 12 months after start HAART (280 copies/ml);

  • patient 14 one positive test 14 months after start HAART (98 copies/ml); last exam after n months = last examination of the patient at n months after the start of HAART.